The Hydration Pharmaceuticals Co (ASX:HPC) Debt-to-EBITDA : -0.37 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is The Hydration Pharmaceuticals Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Hydration Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. The Hydration Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$5.82 Mil. The Hydration Pharmaceuticals Co's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-15.94 Mil. The Hydration Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for The Hydration Pharmaceuticals Co's Debt-to-EBITDA or its related term are showing as below:

ASX:HPC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.52 Med: -0.44 Max: -0.35
Current: -0.52

During the past 3 years, the highest Debt-to-EBITDA Ratio of The Hydration Pharmaceuticals Co was -0.35. The lowest was -0.52. And the median was -0.44.

ASX:HPC's Debt-to-EBITDA is ranked worse than
100% of 251 companies
in the Retail - Defensive industry
Industry Median: 2.55 vs ASX:HPC: -0.52

The Hydration Pharmaceuticals Co Debt-to-EBITDA Historical Data

The historical data trend for The Hydration Pharmaceuticals Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Hydration Pharmaceuticals Co Debt-to-EBITDA Chart

The Hydration Pharmaceuticals Co Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.35

-0.52

The Hydration Pharmaceuticals Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	N/A	-	-0.24	-0.58	-0.37

Competitive Comparison of The Hydration Pharmaceuticals Co's Debt-to-EBITDA

For the Food Distribution subindustry, The Hydration Pharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Hydration Pharmaceuticals Co's Debt-to-EBITDA Distribution in the Retail - Defensive Industry

For the Retail - Defensive industry and Consumer Defensive sector, The Hydration Pharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where The Hydration Pharmaceuticals Co's Debt-to-EBITDA falls into.

The Hydration Pharmaceuticals Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Hydration Pharmaceuticals Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	5.816)	/	-11.144
	=	-0.52

The Hydration Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	5.816)	/	-15.94
	=	-0.36

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

The Hydration Pharmaceuticals Co (ASX:HPC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The Hydration Pharmaceuticals Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of The Hydration Pharmaceuticals Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

The Hydration Pharmaceuticals Co (ASX:HPC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Retail - Defensive » The Hydration Pharmaceuticals Co Ltd (ASX:HPC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Palmer Parade, Level 2, Cremorne, Melbourne, VIC, AUS, 3121

Website

https://www.hydralyte.com

The Hydration Pharmaceuticals Co Ltd is engaged in the marketing and sale of liquid, tablet and powder hydration solution products into the North American markets of Canada and the United States. Some of its products include Hydration + Immune System Boost, Effervescent Electrolyte Tablets, Oral Rehydration Solution, and Immunity Booster Bundle.

The Hydration Pharmaceuticals Co (ASX:HPC) Headlines

No Headlines